MARKET

BLCM

BLCM

Bellicum Pharmaceuticals Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.460
+0.110
+8.15%
After Hours: 1.400 -0.06 -4.11% 18:12 05/27 EDT
OPEN
1.410
PREV CLOSE
1.350
HIGH
1.469
LOW
1.410
VOLUME
23.05K
TURNOVER
0
52 WEEK HIGH
4.040
52 WEEK LOW
1.340
MARKET CAP
12.57M
P/E (TTM)
-8.0396
1D
5D
1M
3M
1Y
5Y
Bellicum Pharmaceuticals Files $200 Million Mixed Shelf
MT Newswires · 05/16 03:47
BRIEF-Bellicum Files For Mixed Shelf Of Up To $200 Million
reuters.com · 05/13 20:23
Bellicum Pharmaceuticals GAAP EPS of -$0.25 beats by $0.42
Bellicum Pharmaceuticals press release (NASDAQ:BLCM): Q1 GAAP EPS of -$0.25 beats by $0.42. Bellicum reported cash and cash equivalents and restricted cash totaling $41.3 million as of March 31, 2022,
Seekingalpha · 05/12 20:45
Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
HOUSTON, May 02, 2022 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced equity inducement grants to 3 new employees consisting of an aggregate ...
GlobeNewswire · 05/02 11:30
Bellicum Pharmaceuticals Q4 EPS $0.11 Down From $0.98 YoY, Sales $500.00K, Same YoY
Bellicum Pharmaceuticals (NASDAQ:BLCM) reported quarterly earnings of $0.11 per share. This is a 88.78 percent decrease over earnings of $0.98 per share from the same period last year. The company reported $500.00
Benzinga · 03/24 20:19
-- Earnings Flash (BLCM) BELLICUM PHARMACEUTICALS Posts Q4 Revenue $500,000
MT Newswires · 03/24 16:13
5 Value Stocks To Watch In The Healthcare Sector
What are Value Stocks?
Benzinga · 03/14 14:43
--Ladenburg Thalmann Initiates Bellicum Pharmaceuticals at Buy with $5 Price Target
MT Newswires · 02/16 09:45
More
No Data
Learn about the latest financial forecast of BLCM. Analyze the recent business situations of Bellicum Pharmaceuticals Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

100.00%Strong Buy
0.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average BLCM stock price target is 5.00 with a high estimate of 5.00 and a low estimate of 5.00.
High5.00
Average5.00
Low5.00
Current 1.460
EPS
Actual
Estimate
-1.07-0.77-0.47-0.16
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 90
Institutional Holdings: 9.18M
% Owned: 106.59%
Shares Outstanding: 8.61M
TypeInstitutionsShares
Increased
3
31.44K
New
8
329.01K
Decreased
5
70.11K
Sold Out
3
21.88K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+3.72%
Pharmaceuticals & Medical Research
+1.28%
Key Executives
Non-Executive Chairman/Independent Director
James Brown
President/Chief Executive Officer/Director
Richard Fair
Other
Charity Scripture
Independent Director
James Daly
Independent Director
Stephen Davis
Independent Director
Reid Huber
Independent Director
Judith Klimovsky
Independent Director
Jon Stonehouse
No Data
No Data
About BLCM
Bellicum Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company focused on discovering and developing controllable cellular immunotherapies for the treatment of various forms of cancer. The Company has developed CAR-T product candidates in cellular immunotherapy through which a patient’s or donor’s T cells are genetically modified to carry chimeric antigen receptors (CARs). It uses a Chemical Induction of Dimerization (CID) technology platform to engineer its product candidates with switch technologies that are designed to control components of the immune system in real time. The Company's product candidates include BPX-601 and BPX-603. The BPX-601, is an autologous GoCAR-T product candidate containing iMC activation switch, designed to treat solid tumors expressing prostate stem cell antigen (PSCA). The BPX-603, is a controllable dual-switch autologous GoCAR-T product candidate, which incorporates both the iMC activation switch and the CaspaCIDe safety switch.

Webull offers kinds of Bellicum Pharmaceuticals Inc stock information, including NASDAQ:BLCM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BLCM stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading BLCM stock methods without spending real money on the virtual paper trading platform.